Healthcare Services

Increasing diabetes cases are driving growth in endocrine peptide testing market

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Endocrine Peptide Test Market During 2026–2030?

The endocrine peptide test market has experienced significant growth in recent years. It is anticipated to expand from $9.95 billion in 2025 to $10.88 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. The market’s past growth can be attributed to an increase in endocrine disorders, the proliferation of diagnostic laboratories, heightened awareness of hormone imbalances, advancements in immunoassay techniques, and the expansion of clinical endocrinology.

The market for endocrine peptide tests is projected to experience robust expansion in the coming years. This market is set to reach $14.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. Factors driving this growth during the forecast period include the increasing adoption of precision medicine, advancements in biomarker research, greater automation in diagnostic laboratories, the rise of personalized endocrine care, and the growing demand for early diagnosis. Key trends anticipated for this period encompass a heightened demand for diagnostics related to hormone disorders, an expanding application of peptide biomarkers, an increase in the early detection of endocrine diseases, the broadening of specialized laboratory testing services, and an emphasis on precise hormonal monitoring.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Which Key Factors Are Driving The Endocrine Peptide Test Market Growth?

The increasing incidence of diabetes is anticipated to stimulate the expansion of the endocrine peptide test market moving forward. Diabetes refers to a collection of illnesses that lead to elevated blood sugar (glucose) levels. The occurrence of diabetes is expanding due to elements such as unhealthy eating habits, inactive lifestyles, genetic susceptibility, and an aging populace. Endocrine peptide tests, encompassing hemoglobin A1c, fasting plasma glucose, and C-peptide tests, are employed in diabetes to identify the condition, monitor glucose concentrations, and evaluate insulin creation and sensitivity. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported that the count of people under 40 diagnosed with diabetes grew considerably, climbing from 173,166 in 2022 to 216,440 in 2023. This significant increase highlights a concerning pattern of rising diabetes rates within younger demographics. Hence, the escalating prevalence of diabetes is fostering the endocrine peptide test market.

What Are The Key Segment Divisions In The Endocrine Peptide Test Market Segment Structure?

The endocrine peptide test market covered in this report is segmented –

1) By Test-Type: Dehydroepiandrosterone Sulphate, Progesterone, Luteinizing Hormone, Thyroid Prolactin, Oestradiol, Human Chorionic Gonadotropin, Thyroid-Stimulating Hormone, Other Test-Types

2) By Technology: Mass Spectroscopy, Immunoassay, Chromatography, Nucleic Acid Based, Other Technologies

3) By End-User: Clinics, Healthcare Centers, Hospitals, Commercial Laboratories

Subsegments:

1) By Dehydroepiandrosterone Sulphate (DHEA-S): Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)

2) By Progesterone: Immunoassay Tests, Chemiluminescence Assays, ELISA Tests

3) By Luteinizing Hormone: Immunoassay Tests, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA)

4) By Thyroid Prolactin: Immunoassay Tests, Chemiluminescence Assays, Radioimmunoassay (RIA)

5) By Oestradiol: Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)

6) By Human Chorionic Gonadotropin (hCG): Immunoassay Tests, Chemiluminescence Assays, Enzyme Immunoassay (EIA)

7) By Thyroid-Stimulating Hormone (TSH): Immunoassay Tests, Radioimmunoassay (RIA), Enzyme-Linked Immunosorbent Assay (ELISA)

8) By Other Test-Types: Cortisol, Insulin, Growth Hormone (GH), Parathyroid Hormone (PTH)

Which Trends Are Guiding The Direction Of The Endocrine Peptide Test Market?

Leading companies in the endocrine peptide test market are developing immunoassay testing systems to enhance the accuracy, sensitivity, and speed of endocrine peptide testing. These systems utilize antibodies to detect and quantify specific peptides in blood or urine samples, supplying healthcare professionals with vital information concerning hormone levels and endocrine function. For example, in July 2023, Siemens Healthineers, a German-based healthcare services company, introduced the Atellica CI Analyzer, a compact instrument for immunoassay and clinical chemistry testing, which includes endocrine peptide assays. This analyzer also offers a reproductive endocrinology menu that features anti-Mullerian hormone (AMH) for determining ovarian reserve, as well as sFlt-1 and PlGF (placental growth factor) to assist in the prognosis of preeclampsia. The Atellica CI Analyzer is engineered to deliver reliable results quickly and uniformly, with a capacity of up to 1000 tests per hour. It provides laboratories with workflow efficiency and flexibility, helping them to meet evolving testing demands.

Which Organizations Are Engaged In The Endocrine Peptide Test Market?

Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories

Get The Full Endocrine Peptide Test Market Report:

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Which Region Represents The Largest Share Of The Endocrine Peptide Test Market?

North America was the largest region in the endocrine peptide test market in 2025. The regions covered in the endocrine peptide test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Endocrine Peptide Test Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Browse Through More Reports Similar to the Global Endocrine Peptide Test Market 2026, By The Business Research Company

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Endocrine Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/endocrine-testing-global-market-report

Thyroid Function Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795